Validation of Procalcitonin as a Biomarker Diagnosing CDI — (DIRT II)

Cardiac Implantable Electronic Device Infections Clinical Trial

Official title:
A Prospective Case-control Validation of Procalcitonin as a Biomarker Diagnosing Pacemaker and Implantable Cardioverter Defibrillator Pocket Infection

Status Completed

Clinical Trial Summary

Cardiac device infections (CDI), especially pocket infections, are difficult to be diagnosed. Device pocket infections are not associated with elevated white blood cell count. CRP is only assoziated with a low sensitivity. The diagnosis of a local pocket infection is challenging and relies primarily on the clinical presentation. The prospective DIRT study identified procalcitonin (PCT) among 14 biomarkers as the most promising biomarker to aid the diagnosis of pocket infection. The study aims to validate the proposed PCT cut-off value of 0.05 ng/ml for the diagnosis of pocket infection

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiac Implantable Electronic Device Infections
Infections

Clinical Trial Details

NCT number	NCT05007158
Study type	Observational [Patient Registry]
Source	Deutsches Herzzentrum Muenchen
Contact
Status	Completed
Phase
Start date	December 1, 2011
Completion date	November 1, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05103267` - Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients
	Completed	`NCT04501835` - Assessment of Diagnostic and Therapeutic Practices for Cardiac Implantable Electronic Devices Suspected Infections in Nancy University Hospital